• Return to Headlines

Shares of Neurocrine Biosc Has Risen Above Previous 52-Week High

By Shiri Gupta

Neurocrine Biosc (NASDAQ:NBIX) traded today at a new 52-week high of $55.50. Approximately 200,000 shares have changed hands today, as compared to an average 30-day volume of 1 million shares.

Neurocrine Biosc share prices have moved between a 52-week high of $55.50 and a 52-week low of $37.34 and are now trading 49% above that low price at $55.46 per share. Over the past week, the 200-day moving average (MA) has gone down 0.4% while the 50-day MA has advanced 1.5%.

Neurocrine Biosc (NASDAQ:NBIX) has potential upside of 29.7% based on a current price of $55.46 and analysts' consensus price target of $71.92. The stock should discover initial support at its 200-day moving average (MA) of $46.05 and subsequent support at its 50-day MA of $40.85.

Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The Company is developing therapeutic interventions for anxiety, depression, alzheimer's disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity, and diabetes.

SmarTrend recommended that subscribers consider buying shares of Neurocrine Biosc on July 25th, 2017 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $49.08. Since that recommendation, shares of Neurocrine Biosc have risen 9.6%. We continue to monitor NBIX for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: 52 week high/lows neurocrine biosc

Ticker(s): NBIX